Targeting CDK4 in TGS-B Inactivated Gastrointestinal Cancers
TGS-B 灭活胃肠道癌中靶向 CDK4
基本信息
- 批准号:8744873
- 负责人:
- 金额:$ 17.08万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-09-01 至 2016-08-31
- 项目状态:已结题
- 来源:
- 关键词:AccountingAdverse effectsAnimal ModelAntineoplastic AgentsBiological ModelsCDC2 Protein KinaseCDK2 geneCDK4 geneCell CycleCell Cycle ProgressionCell Cycle ProteinsCell DeathCell ProliferationCessation of lifeClinical TrialsCyclin D1Cyclin-Dependent Kinase Inhibitor 2ADevelopmentDrug KineticsEvaluationExhibitsFamilyG1 PhaseGrowthHeterozygoteHumanIncidenceKineticsKnock-outLibrariesLightMalignant NeoplasmsMalignant neoplasm of gastrointestinal tractMolecularMusNormal CellPharmaceutical PreparationsPreventivePrimitive foregut structureRoleSafetyScaffolding ProteinSignal TransductionStructure-Activity RelationshipTGFB1 geneTestingTherapeutic AgentsTreatment ProtocolsTumor Suppressor Proteinsbasecancer cellcancer therapycell transformationcross reactivitydrug candidatedrug discoveryflavopiridolhuman TGFBR2 proteininhibitor/antagonistkinase inhibitorneoplastic cellnovelpreclinical studyprotein expressionresponsesmall moleculesmall molecule librariestranscription factortumor
项目摘要
Recent studies have shown that TGF-B inhibits cell proliferation by blocking cell cycle progression at the G1 phase of the cell cycle and hence, is thought to function as a tumor suppressor protein. Most human cancers appear to have lost their growth-inhibitory response to TGF-B. Our preliminary studies show that foregut cancers with inactivation of TGF-B signaling express high levels of cyclin D1 and CDK4 levels, suggesting that the deregulated expression of these proteins may contribute to the development of these tumors. Flavopiridol, an established Cdk inhibitor used in treatment protocols for certain cancers, is known to inhibit most known CDKs especially against CDKs 7, 8 and 9, is thought to be largely responsible for the toxic side effects caused by this drug in clinical trials. In light of these observations, we have screened a compound library of kinase inhibitors for CDK-4 specific inhibition and isolated two novel molecules (ON55290 and ON27900) which exhibit CDK4 inhibitory activity. In this application, we propose to carry out pre-clinical studies to test the usefulness of these molecules in gastrointestinal cancer therapy. The aims of the proposal are:
1. To further validate the role of CDK4 in Elf+/-, Elf+/-:Smad3+/- tumor model system through evaluation of tumor incidence in CDK4+/V El+/- : CDK4+/-: Elf/Elf[+]-Smad4[+/-] and CDK4[+/-]; Elf¿/Elf+:Smad4+/- mice.
2. (a) To expand the chemical library in an effort to understand the structure-activity relationship (SAR) of CDK4 inhibitors and (b) to conduct a detailed kinetic analysis of CDK4 inhibition by ON55290 and ON27900 to gain critical information on the mechanisms by which these compounds elicit their inhibitory effects on CDK4.
3. To determine the molecular mechanisms by which ON55290 and ON27900 bring about growth arrest and death of human gastrointestinal cancer cells. 4. To assess the safety and pharmacokinetics of the candidate drug in animal models of gastrointestinal cancers that develop in the TGF-f3 inactivated state.
最近的研究表明,TGF-B通过在细胞周期的G1期阻断细胞周期进程来抑制细胞增殖,因此被认为是一种肿瘤抑制蛋白。大多数人类癌症似乎已经失去了对TGF-B的生长抑制反应。我们的初步研究表明,TGF-B信号失活的前肠癌表达高水平的细胞周期蛋白D1和CDK4水平,这表明这些蛋白的表达失调可能有助于这些肿瘤的发展。黄酮吡醇是一种成熟的Cdk抑制剂,用于某些癌症的治疗方案,已知可以抑制大多数已知的Cdk,特别是CDKs 7, 8和9,在临床试验中被认为是该药物引起毒副作用的主要原因。根据这些观察结果,我们筛选了一个具有CDK-4特异性抑制作用的激酶抑制剂化合物库,并分离出两个具有CDK4抑制活性的新分子(ON55290和ON27900)。在这项应用中,我们建议进行临床前研究,以测试这些分子在胃肠道癌症治疗中的有效性。该建议的目的是:
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
E Premkumar Reddy其他文献
IL-3 signaling and the role of Src kinases, JAKs and STATs: a covert liaison unveiled
白细胞介素 3 信号传导以及 Src 激酶、JAK 和 STAT 的作用:一个隐蔽的联络被揭示
- DOI:
10.1038/sj.onc.1203594 - 发表时间:
2000-05-25 - 期刊:
- 影响因子:7.300
- 作者:
E Premkumar Reddy;Anita Korapati;Priya Chaturvedi;Sushil Rane - 通讯作者:
Sushil Rane
Janus kinases: components of multiple signaling pathways
Janus 激酶:多条信号通路的组成部分
- DOI:
10.1038/sj.onc.1203925 - 发表时间:
2000-11-20 - 期刊:
- 影响因子:7.300
- 作者:
Sushil G Rane;E Premkumar Reddy - 通讯作者:
E Premkumar Reddy
The myb gene family in cell growth, differentiation and apoptosis
细胞生长、分化和凋亡中的 myb 基因家族
- DOI:
10.1038/sj.onc.1202839 - 发表时间:
1999-05-13 - 期刊:
- 影响因子:7.300
- 作者:
Il-Hoan Oh;E Premkumar Reddy - 通讯作者:
E Premkumar Reddy
JAKs, STATs and Src kinases in hematopoiesis
造血过程中的 JAKs、STATs 和 Src 激酶
- DOI:
10.1038/sj.onc.1205398 - 发表时间:
2002-05-21 - 期刊:
- 影响因子:7.300
- 作者:
Sushil G Rane;E Premkumar Reddy - 通讯作者:
E Premkumar Reddy
Signaling by dual specificity kinases
双特异性激酶的信号传导
- DOI:
10.1038/sj.onc.1202251 - 发表时间:
1998-09-22 - 期刊:
- 影响因子:7.300
- 作者:
N Dhanasekaran;E Premkumar Reddy - 通讯作者:
E Premkumar Reddy
E Premkumar Reddy的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('E Premkumar Reddy', 18)}}的其他基金
Targeting FL3 and SRC kinases for AML therapy
靶向 FL3 和 SRC 激酶进行 AML 治疗
- 批准号:
10658259 - 财政年份:2023
- 资助金额:
$ 17.08万 - 项目类别:
Targeting cell cycle and metabolic pathways of high risk breast cancers using mouse models of hyperinsulinemia
使用高胰岛素血症小鼠模型靶向高风险乳腺癌的细胞周期和代谢途径
- 批准号:
10671005 - 财政年份:2020
- 资助金额:
$ 17.08万 - 项目类别:
Targeting cell cycle and metabolic pathways of high risk breast cancers using mouse models of hyperinsulinemia
使用高胰岛素血症小鼠模型靶向高风险乳腺癌的细胞周期和代谢途径
- 批准号:
10199970 - 财政年份:2020
- 资助金额:
$ 17.08万 - 项目类别:
Targeting cell cycle and metabolic pathways of high risk breast cancers using mouse models of hyperinsulinemia
使用高胰岛素血症小鼠模型靶向高风险乳腺癌的细胞周期和代谢途径
- 批准号:
10029076 - 财政年份:2020
- 资助金额:
$ 17.08万 - 项目类别:
Targeting cell cycle and metabolic pathways of high risk breast cancers using mouse models of hyperinsulinemia
使用高胰岛素血症小鼠模型靶向高风险乳腺癌的细胞周期和代谢途径
- 批准号:
10457279 - 财政年份:2020
- 资助金额:
$ 17.08万 - 项目类别:
Targeting Mitotic Kinases Inhibitors for Cancer Therapy
靶向有丝分裂激酶抑制剂用于癌症治疗
- 批准号:
8985660 - 财政年份:2012
- 资助金额:
$ 17.08万 - 项目类别:
Targeting Mitotic Kinases Inhibitors for Cancer Therapy
靶向有丝分裂激酶抑制剂用于癌症治疗
- 批准号:
8787991 - 财政年份:2012
- 资助金额:
$ 17.08万 - 项目类别:
Targeting Mitotic Kinases Inhibitors for Cancer Therapy
靶向有丝分裂激酶抑制剂用于癌症治疗
- 批准号:
8435360 - 财政年份:2012
- 资助金额:
$ 17.08万 - 项目类别:
Targeting Mitotic Kinases Inhibitors for Cancer Therapy
靶向有丝分裂激酶抑制剂用于癌症治疗
- 批准号:
8238575 - 财政年份:2012
- 资助金额:
$ 17.08万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 17.08万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 17.08万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 17.08万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 17.08万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 17.08万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 17.08万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 17.08万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 17.08万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 17.08万 - 项目类别:
Downsides of downhill: The adverse effects of head vibration associated with downhill mountain biking on visuomotor and cognitive function
速降的缺点:与速降山地自行车相关的头部振动对视觉运动和认知功能的不利影响
- 批准号:
2706416 - 财政年份:2022
- 资助金额:
$ 17.08万 - 项目类别:
Studentship